Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors — a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made this concept a reality, crafting what they have named the “EchoBack CAR T-cell,” which could soon be a game changer in the field of cancer immunotherapy.The work, published in the scientific journal Cell, is a groundbreaking new approach that could overcome major obstacles in treating tumors that are not usually candidates for immunotherapy, while keeping healthy tissue safe.

Nearly 16 million American adults have been diagnosed with attention deficit hyperactivity disorder (ADHD), but evidence suggests that more than 30 percent of them don’t respond well to stimulant medications like Ritalin and Adderall. A new clinical trial provides a surprising explanation for why this may be the case: There are individual differences in how our brains circuits are wired, including the chemical circuits responsible for memory and concentration, according to a new study co-led by the University of Maryland School of Medicine (UMSOM) and performed at the National Institutes of Health (NIH) Clinical Center.

CSHL Professor David Tuveson and Research Investigator Claudia Tonelli have found a way to “intercept” pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able to prevent pancreatic cancer from forming in the first place.